Apogenix develops innovative immuno-oncology therapeutics for the treatment of solid tumors and malignant hematological diseases.
The company’s lead immuno-oncology candidate asunercept has been shown to prolong overall survival in a phase II trial in recurrent glioblastoma – the most frequent and aggressive brain tumor – and has demonstrated hematological improvements in a phase I trial in myelodysplastic syndromes (MDS) – a stem cell disorder that can lead to severe anemia.
Apogenix has also developed a proprietary technology platform for the construction of novel TNF superfamily receptor agonists (HERA-ligands) which stimulate and enhance the anti-tumor immune response and have the potential for broad application in oncology.
Apogenix at a glance:
|Field of Activity
||Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the anti-tumor immune response.|
|Ownership Structure and Financing||Apogenix is privately held and has raised more than 100 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements.|
|Products/Services||Asunercept: CD95 ligand inhibitor asunercept is in late-stage clinical development for the treatment of glioblastoma and MDS. It has received PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. Preclinical studies in other solid tumors demonstrate the potential of asunercept in a broad range of oncology indications.
HERA-ligands: Apogenix’ HERA-ligands are being developed for the treatment of hematologic and solid tumors. They have shown strong anti-tumor efficacy in vitro and in vivo, with a benign safety profile.
|Technology and Unique Selling Point||Apogenix has developed the proprietary HERA-ligand technology platform for the construction of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These HERA-ligands overcome the structural limitations of other biologics targeting TNFSF pathways, such as antibodies.|
|Date of Incorporation/
Number of Employees
|Address||Im Neuenheimer Feld 584
|Telephone/Telefax||+49 6221 58608-0/-10|